A guide to selecting high-performing renewable antibodies for SCARB2 across western blot, immunoprecipitation, and immunofluorescence
Authors/Creators
- 1. The Montreal Neurological Institute
Contributors
Researcher:
Description
Here we have characterized twelve SCARB2 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. This research was partly funded by the G-Can (GBA1-Canada) initiative, an open-science collaboration dedicated to advancing research on Parkinson's disease associated with GBA1 mutations. G-Can is supported by The Hilary & Galen Weston Foundation, Silverstein Foundation, and J. Sebastian van Berkom and Ghislaine Saucier. This work was also supported by a grant from the Quebec Consortium for Drug Discovery (CQDM), a grant from the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec.
Files
SCARB2_YCharOS report - v6.pdf
Files
(1.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:9a2098103fe59bec8b48009a116709c9
|
1.7 MB | Preview Download |